Insider · CIK 0001708133
Jonathan E Freeman
Files at PHIO (Phio Pharmaceuticals Corp.). First filing -, latest -.
In brief
Jonathan E Freeman files SEC Form 4 as director at PHIO (Phio Pharmaceuticals Corp.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jonathan E Freeman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 5, 2026 | PHIO Phio Pharmaceuticals Corp. | AGrant or award Common Stock, $.0001 par value | +16,600 | $0.00 | $0 | 32,655 | Feb 6, 2026 |
| Sep 11, 2025 | PHIO Phio Pharmaceuticals Corp. | AGrant or award Common Stock, $.0001 par value | +14,700 | $0.00 | $0 | 16,055 | Sep 15, 2025 |
Questions about Jonathan E Freeman
Answered from the filings on this page, as of the latest one.
Is Jonathan E Freeman buying or selling?
Jonathan E Freeman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jonathan E Freeman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jonathan E Freeman has 0.
Where does Jonathan E Freeman file Form 4?
Jonathan E Freeman has filed Form 4 at PHIO (Phio Pharmaceuticals Corp.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.